胆固醇酯转移蛋白抑制剂在动脉粥样硬化性心血管疾病治疗中的研究进展  

Treatment of Atherosclerotic Cardiovascular Disease with Cholesteryl Ester Transfer Protein Inhibitors

作　　者：朱洁 高奋[2] 薛拴勤 陈丽君 ZHU Jie;GAO Fen;XUE Shuanqin;CHEN Lijun(Shanxi Medical University,Taiyuan 030000,Shanxi,China;Cardiovascular Department,The Second Hospital of Shanxi Medical University,Taiyuan 030000,Shanxi,China)

机构地区：[1]山西医科大学,山西太原030000 [2]山西医科大学第二医院心内科,山西太原030000

出　　处：《心血管病学进展》2022年第7期600-604,共5页Advances in Cardiovascular Diseases

基　　金：山西省重点研发计划项目(201903D321185)。

摘　　要：动脉粥样硬化性心血管疾病与多种因素相关,其中血脂异常占有极其重要的地位。胆固醇酯转移蛋白抑制剂是一种以升高高密度脂蛋白胆固醇为目标的调血脂药,可联合他汀类药物在降低低密度脂蛋白胆固醇的基础上升高高密度脂蛋白胆固醇水平,从而降低高危患者心血管不良事件风险。现将胆固醇酯转移蛋白抑制剂的作用机制、研究现状和未来前景等进行综述。Atherosclerotic cardiovascular disease is associated with a number of factors,of which dyslipidaemia plays an important role.Cholesteryl ester transfer protein inhibitors are lipid-modifying drugs that aim to increase high-density lipoprotein cholesterol.It can be combined with statins to increase the level of high-density lipoprotein cholesterol on the basis of reducing low-density lipoprotein cholesterol,thereby reducing the risk of cardiovascular events in high-risk patients.This article reviews the mechanism of action,research status and future prospects of cholesteryl ester transfer protein inhibitors.

关 键 词：动脉粥样硬化性心血管疾病 胆固醇酯转移蛋白 胆固醇酯转移蛋白抑制剂 

分 类 号：R54[医药卫生—心血管疾病]